Avinger (NASDAQ:AVGR) had its price objective decreased by stock analysts at Aegis from $1.40 to $1.00 in a note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the medical device company’s stock. Aegis’ target price would indicate a potential upside of 175.18% from the stock’s current price.

Separately, Zacks Investment Research upgraded shares of Avinger from a “hold” rating to a “buy” rating and set a $0.50 price target for the company in a research note on Tuesday.

Shares of NASDAQ:AVGR traded up $0.02 during midday trading on Wednesday, hitting $0.36. The company’s stock had a trading volume of 162,571 shares, compared to its average volume of 19,065,438. The stock has a market capitalization of $28.78 million, a price-to-earnings ratio of -0.19 and a beta of 1.57. The stock’s 50 day simple moving average is $0.49 and its 200 day simple moving average is $0.42. Avinger has a fifty-two week low of $0.24 and a fifty-two week high of $1.63. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.14 and a current ratio of 1.39.

Avinger (NASDAQ:AVGR) last released its earnings results on Thursday, July 30th. The medical device company reported ($0.18) earnings per share for the quarter. Avinger had a negative return on equity of 283.92% and a negative net margin of 225.26%. The firm had revenue of $1.47 million for the quarter. As a group, analysts anticipate that Avinger will post -0.92 EPS for the current year.

A hedge fund recently bought a new stake in Avinger stock. Sabby Management LLC acquired a new position in Avinger Inc (NASDAQ:AVGR) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 568,400 shares of the medical device company’s stock, valued at approximately $236,000. Avinger comprises approximately 0.1% of Sabby Management LLC’s investment portfolio, making the stock its 24th largest position. Sabby Management LLC owned 1.93% of Avinger as of its most recent SEC filing. Institutional investors own 8.59% of the company’s stock.

Avinger Company Profile

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Recommended Story: Buyback

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.